James Hilger

Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up

Judith Trotman, Stephen Opat, David Gottlieb et al. · Blood · 2020 · 105 citations · Full text

ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

Peter Hillmen, Jennifer R. Brown, Barbara Eichhorst et al. · Future Oncology · 2020 · 80 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Btk Occupancy +13

Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy

James R. Berenson, James Hilger, Ori Yellin et al. · Leukemia · 2014 · 76 citations · Full text

Ascorbic Acid, Hematological Malignancy, Oncology +13

Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma from a Phase 2 Trial

Yuqin Song, Keshu Zhou, Dehui Zou et al. · Blood · 2018 · 38 citations

A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma

James R. Berenson, James Hilger, Ori Yellin et al. · Annals of Hematology · 2013 · 36 citations

Phase 1/2, Hematological Malignancy, Oral Panobinostat +9